Dr. Meeker is the President & CEO of KSQ, a biotech company with a proprietary CRISPRomics drug discovery engine. Utilizing this engine, KSQ is advancing a pipeline of oncology and immuno-oncology drug development programs. Dr. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the executive committee.
In his career with Genzyme, Dr. Meeker held key positions of increasing responsibility beginning in the R&D organization and subsequently in operating roles, culminating in the position of Chief Operating Officer at the time of the merger. In his most recent role within Sanofi, he headed Sanofi-Genzyme, the specialty care unit with responsibility for Rare Diseases, MS, Oncology and Immunology franchises.
Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He completed his internal medicine training at Harvard’s Beth Israel Hospital and his pulmonary/critical training at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.
Dr. Meeker is the Chairman of the Board of Rhythm Pharmaceuticals, and Trevi Therapeutics and a member of the board at Myokardia. He also serves on the boards of the Biomedical Science Careers Program, the Network for Excellence in Health Innovation and the Dimock Center, a Boston based community health center.